Skip to main content
. 2017 Jul 18;7:5690. doi: 10.1038/s41598-017-05836-6

Figure 6.

Figure 6

Effect of AMPK agonist, AICAR, on TGF-β-induced EMT and Alteration of Intracellular Signaling Pathways. AICAR (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide, 10 μM) alleviates TGF-β1-induced changes in cell morphology (A) and the expression of E-cadherin and α-SMA (B). AICAR does not block an activation of Smad2/3 pathway (30 minutes) and MAPK phosphorylation (3 hours) (C). Representative cell morphology (A) and western blotting with quantitation graph are shown (BD). N = 6. *p < 0.05 vs. others, #p < 0.05 vs. TGF-β1.